JP6373252B2 - オーロラキナーゼ阻害薬を使用する癌の治療方法 - Google Patents

オーロラキナーゼ阻害薬を使用する癌の治療方法 Download PDF

Info

Publication number
JP6373252B2
JP6373252B2 JP2015501852A JP2015501852A JP6373252B2 JP 6373252 B2 JP6373252 B2 JP 6373252B2 JP 2015501852 A JP2015501852 A JP 2015501852A JP 2015501852 A JP2015501852 A JP 2015501852A JP 6373252 B2 JP6373252 B2 JP 6373252B2
Authority
JP
Japan
Prior art keywords
aurora
cancer
paclitaxel
kinase
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015501852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510945A5 (Direct
JP2015510945A (ja
Inventor
アリジット チャクラバーティ，
アリジット チャクラバーティ，
ジェフリー エー． エクセディ，
ジェフリー エー． エクセディ，
ロバート ダブリュー． クレインフィールド，
ロバート ダブリュー． クレインフィールド，
カー エヌ． リ，
カー エヌ． リ，
ウェン チー シュー，
ウェン チー シュー，
カルシク ベンカタクリシュナン，
カルシク ベンカタクリシュナン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2015510945A publication Critical patent/JP2015510945A/ja
Publication of JP2015510945A5 publication Critical patent/JP2015510945A5/ja
Application granted granted Critical
Publication of JP6373252B2 publication Critical patent/JP6373252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015501852A 2012-03-20 2013-03-19 オーロラキナーゼ阻害薬を使用する癌の治療方法 Active JP6373252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
US61/613,258 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015510945A JP2015510945A (ja) 2015-04-13
JP2015510945A5 JP2015510945A5 (Direct) 2016-05-12
JP6373252B2 true JP6373252B2 (ja) 2018-08-15

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501852A Active JP6373252B2 (ja) 2012-03-20 2013-03-19 オーロラキナーゼ阻害薬を使用する癌の治療方法

Country Status (24)

Country Link
US (2) US20130303519A1 (Direct)
EP (1) EP2827855B1 (Direct)
JP (1) JP6373252B2 (Direct)
KR (1) KR102128866B1 (Direct)
CN (1) CN104271129A (Direct)
AU (1) AU2013235275B2 (Direct)
CA (1) CA2868024A1 (Direct)
EA (1) EA036434B1 (Direct)
ES (1) ES2746946T3 (Direct)
GE (2) GEP20186900B (Direct)
IL (1) IL234686B (Direct)
IN (1) IN2014DN08477A (Direct)
JO (1) JO3630B1 (Direct)
MA (1) MA37438A1 (Direct)
MX (1) MX358411B (Direct)
MY (1) MY175225A (Direct)
NZ (1) NZ700744A (Direct)
PH (1) PH12014502109A1 (Direct)
SG (2) SG11201405621UA (Direct)
TN (1) TN2014000387A1 (Direct)
TW (1) TWI649082B (Direct)
UA (1) UA117455C2 (Direct)
WO (1) WO2013142491A1 (Direct)
ZA (1) ZA201407551B (Direct)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190194750A1 (en) * 2015-07-02 2019-06-27 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
WO1999016770A1 (en) 1997-09-29 1999-04-08 Meiji Seika Kaisha, Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
KR100909122B1 (ko) 2001-08-09 2009-07-23 액테리온 파마슈티칼 리미티드 신규한 벤조-융합된 헤테로환
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20050249806A1 (en) 2004-02-10 2005-11-10 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug
KR20120091275A (ko) 2004-05-14 2012-08-17 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 방법
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
BRPI0620341A2 (pt) 2005-12-23 2011-11-08 Smithkline Beecham Corparation azaindóis inibidores de cinases aurora
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
WO2008020314A2 (en) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
BRPI0718100A2 (pt) 2006-10-31 2013-11-05 Achillion Pharmaceuticals Inc Composições farmacêuticas de elvucitabina
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
GEAP201813599A (en) 2018-06-25
US10213436B2 (en) 2019-02-26
US20160193224A1 (en) 2016-07-07
MX2014011324A (es) 2014-12-05
US20130303519A1 (en) 2013-11-14
MA37438A1 (fr) 2016-05-31
EP2827855B1 (en) 2019-06-26
HK1206253A1 (en) 2016-01-08
MX358411B (es) 2018-08-20
UA117455C2 (uk) 2018-08-10
TN2014000387A1 (en) 2015-12-21
TWI649082B (zh) 2019-02-01
SG10201607741RA (en) 2016-11-29
JO3630B1 (ar) 2020-08-27
IL234686B (en) 2020-01-30
IL234686A0 (en) 2014-11-30
AU2013235275B2 (en) 2017-12-07
KR102128866B1 (ko) 2020-07-01
IN2014DN08477A (Direct) 2015-05-08
ZA201407551B (en) 2019-01-30
EA201491727A1 (ru) 2015-01-30
KR20140144215A (ko) 2014-12-18
PH12014502109A1 (en) 2014-12-10
CN104271129A (zh) 2015-01-07
EP2827855A1 (en) 2015-01-28
EA036434B1 (ru) 2020-11-10
TW201343169A (zh) 2013-11-01
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
SG11201405621UA (en) 2014-10-30
WO2013142491A1 (en) 2013-09-26
ES2746946T3 (es) 2020-03-09
JP2015510945A (ja) 2015-04-13
AU2013235275A1 (en) 2014-10-23
MY175225A (en) 2020-06-16
GEP20186900B (en) 2018-10-10

Similar Documents

Publication Publication Date Title
Hoang et al. Oncogenic signaling of MEK5-ERK5
JP6263468B2 (ja) Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ
JP6757959B2 (ja) 抗がん剤
KR20220030222A (ko) Tead 억제제 및 이의 용도
EP3212650B1 (en) Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
JP2025519119A (ja) Ｍｅｋ阻害剤及びその使用
WO2014177915A1 (en) Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
CN105283178A (zh) 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
CA2782146A1 (en) Small pyrimidine derivatives and methods of use thereof
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
WO2022187849A1 (en) Salinomycin derivatives and uses thereof
CN102105147B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer
EP3324976A1 (en) Administration of aurora kinase inhibitor and chemotherapeutic agents
JP2014034534A (ja) ＨＳＰ９０阻害剤とｍＴＯＲ阻害剤の組み合わせ
JP2014091712A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性タキサン化合物との組み合わせ
JP2014034535A (ja) Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180717

R150 Certificate of patent or registration of utility model

Ref document number: 6373252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250